Defining the critical hurdles in cancer immunotherapy

Bernard A. Fox, Dolores J. Schendel, Lisa H. Butterfield, Steinar Aamdal, James P. Allison, Paolo Antonio Ascierto, Michael B. Atkins, Jirina Bartunkova, Lothar Bergmann, Neil Berinstein, Cristina C. Bonorino, Ernest Borden, Jonathan L. Bramson, Cedrik M. Britten, Xuetao Cao, William E. Carson, Alfred E. Chang, Dainius Characiejus, A. Raja Choudhury, George Coukos & 85 others Tanja de Gruijl, Robert O. Dillman, Harry Dolstra, Glenn Dranoff, Lindy G. Durrant, James H. Finke, Jerome Galon, Jared A. Gollob, Cécile Gouttefangeas, Fabio Grizzi, Michele Guida, Leif Håkansson, Kristen Hege, Ronald B. Herberman, F. Stephen Hodi, Axel Hoos, Christoph Huber, Patrick Hwu, Kohzoh Imai, Elizabeth M. Jaffee, Sylvia Janetzki, Carl H. June, Pawel Kalinski, Howard L. Kaufman, Koji Kawakami, Yutaka Kawakami, Ulrich Keilholtz, Samir N. Khleif, Rolf Kiessling, Beatrix Kotlan, Guido Kroemer, Rejean Lapointe, Hyam I. Levitsky, Michael T. Lotze, Cristina Maccalli, Michele Maio, Jens Peter Marschner, Michael J. Mastrangelo, Giuseppe Masucci, Ignacio Melero, Cornelius Melief, William J. Murphy, Brad Nelson, Andrea Nicolini, Michael I. Nishimura, Kunle Odunsi, Pamela S. Ohashi, Jill O'Donnell-Tormey, Lloyd J. Old, Christian Ottensmeier, Michael Papamichail, Giorgio Parmiani, Graham Pawelec, Enrico Proietti, Shukui Qin, Robert Rees, Antoni Ribas, Ruggero Ridolfi, Gerd Ritter, Licia Rivoltini, Pedro J. Romero, Mohamed L. Salem, Rik J. Scheper, Barbara Seliger, Padmanee Sharma, Hiroshi Shiku, Harpreet Singh-Jasuja, Wenru Song, Per Thor Straten, Hideaki Tahara, Zhigang Tian, Sjoerd H. van der Burg, Paul von Hoegen, Ena Wang, Marij J P Welters, Hauke Winter, Tara Withington, Jedd D. Wolchok, Weihua Xiao, Laurence Zitvogel, Heinz Zwierzina, Francesco M. Marincola, Thomas F. Gajewski, Jon M. Wigginton, Mary L. Disis

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.

Original languageEnglish
Article number214
JournalJournal of Translational Medicine
Volume9
Issue number1
DOIs
Publication statusPublished - 2011 Dec 14

Fingerprint

Immunotherapy
Neoplasms
Research Personnel
North America
Pharmaceutical Preparations
China
Japan
Industry
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Fox, B. A., Schendel, D. J., Butterfield, L. H., Aamdal, S., Allison, J. P., Ascierto, P. A., ... Disis, M. L. (2011). Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 9(1), [214]. https://doi.org/10.1186/1479-5876-9-214

Defining the critical hurdles in cancer immunotherapy. / Fox, Bernard A.; Schendel, Dolores J.; Butterfield, Lisa H.; Aamdal, Steinar; Allison, James P.; Ascierto, Paolo Antonio; Atkins, Michael B.; Bartunkova, Jirina; Bergmann, Lothar; Berinstein, Neil; Bonorino, Cristina C.; Borden, Ernest; Bramson, Jonathan L.; Britten, Cedrik M.; Cao, Xuetao; Carson, William E.; Chang, Alfred E.; Characiejus, Dainius; Raja Choudhury, A.; Coukos, George; de Gruijl, Tanja; Dillman, Robert O.; Dolstra, Harry; Dranoff, Glenn; Durrant, Lindy G.; Finke, James H.; Galon, Jerome; Gollob, Jared A.; Gouttefangeas, Cécile; Grizzi, Fabio; Guida, Michele; Håkansson, Leif; Hege, Kristen; Herberman, Ronald B.; Stephen Hodi, F.; Hoos, Axel; Huber, Christoph; Hwu, Patrick; Imai, Kohzoh; Jaffee, Elizabeth M.; Janetzki, Sylvia; June, Carl H.; Kalinski, Pawel; Kaufman, Howard L.; Kawakami, Koji; Kawakami, Yutaka; Keilholtz, Ulrich; Khleif, Samir N.; Kiessling, Rolf; Kotlan, Beatrix; Kroemer, Guido; Lapointe, Rejean; Levitsky, Hyam I.; Lotze, Michael T.; Maccalli, Cristina; Maio, Michele; Marschner, Jens Peter; Mastrangelo, Michael J.; Masucci, Giuseppe; Melero, Ignacio; Melief, Cornelius; Murphy, William J.; Nelson, Brad; Nicolini, Andrea; Nishimura, Michael I.; Odunsi, Kunle; Ohashi, Pamela S.; O'Donnell-Tormey, Jill; Old, Lloyd J.; Ottensmeier, Christian; Papamichail, Michael; Parmiani, Giorgio; Pawelec, Graham; Proietti, Enrico; Qin, Shukui; Rees, Robert; Ribas, Antoni; Ridolfi, Ruggero; Ritter, Gerd; Rivoltini, Licia; Romero, Pedro J.; Salem, Mohamed L.; Scheper, Rik J.; Seliger, Barbara; Sharma, Padmanee; Shiku, Hiroshi; Singh-Jasuja, Harpreet; Song, Wenru; Straten, Per Thor; Tahara, Hideaki; Tian, Zhigang; van der Burg, Sjoerd H.; von Hoegen, Paul; Wang, Ena; Welters, Marij J P; Winter, Hauke; Withington, Tara; Wolchok, Jedd D.; Xiao, Weihua; Zitvogel, Laurence; Zwierzina, Heinz; Marincola, Francesco M.; Gajewski, Thomas F.; Wigginton, Jon M.; Disis, Mary L.

In: Journal of Translational Medicine, Vol. 9, No. 1, 214, 14.12.2011.

Research output: Contribution to journalArticle

Fox, BA, Schendel, DJ, Butterfield, LH, Aamdal, S, Allison, JP, Ascierto, PA, Atkins, MB, Bartunkova, J, Bergmann, L, Berinstein, N, Bonorino, CC, Borden, E, Bramson, JL, Britten, CM, Cao, X, Carson, WE, Chang, AE, Characiejus, D, Raja Choudhury, A, Coukos, G, de Gruijl, T, Dillman, RO, Dolstra, H, Dranoff, G, Durrant, LG, Finke, JH, Galon, J, Gollob, JA, Gouttefangeas, C, Grizzi, F, Guida, M, Håkansson, L, Hege, K, Herberman, RB, Stephen Hodi, F, Hoos, A, Huber, C, Hwu, P, Imai, K, Jaffee, EM, Janetzki, S, June, CH, Kalinski, P, Kaufman, HL, Kawakami, K, Kawakami, Y, Keilholtz, U, Khleif, SN, Kiessling, R, Kotlan, B, Kroemer, G, Lapointe, R, Levitsky, HI, Lotze, MT, Maccalli, C, Maio, M, Marschner, JP, Mastrangelo, MJ, Masucci, G, Melero, I, Melief, C, Murphy, WJ, Nelson, B, Nicolini, A, Nishimura, MI, Odunsi, K, Ohashi, PS, O'Donnell-Tormey, J, Old, LJ, Ottensmeier, C, Papamichail, M, Parmiani, G, Pawelec, G, Proietti, E, Qin, S, Rees, R, Ribas, A, Ridolfi, R, Ritter, G, Rivoltini, L, Romero, PJ, Salem, ML, Scheper, RJ, Seliger, B, Sharma, P, Shiku, H, Singh-Jasuja, H, Song, W, Straten, PT, Tahara, H, Tian, Z, van der Burg, SH, von Hoegen, P, Wang, E, Welters, MJP, Winter, H, Withington, T, Wolchok, JD, Xiao, W, Zitvogel, L, Zwierzina, H, Marincola, FM, Gajewski, TF, Wigginton, JM & Disis, ML 2011, 'Defining the critical hurdles in cancer immunotherapy', Journal of Translational Medicine, vol. 9, no. 1, 214. https://doi.org/10.1186/1479-5876-9-214
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 2011 Dec 14;9(1). 214. https://doi.org/10.1186/1479-5876-9-214
Fox, Bernard A. ; Schendel, Dolores J. ; Butterfield, Lisa H. ; Aamdal, Steinar ; Allison, James P. ; Ascierto, Paolo Antonio ; Atkins, Michael B. ; Bartunkova, Jirina ; Bergmann, Lothar ; Berinstein, Neil ; Bonorino, Cristina C. ; Borden, Ernest ; Bramson, Jonathan L. ; Britten, Cedrik M. ; Cao, Xuetao ; Carson, William E. ; Chang, Alfred E. ; Characiejus, Dainius ; Raja Choudhury, A. ; Coukos, George ; de Gruijl, Tanja ; Dillman, Robert O. ; Dolstra, Harry ; Dranoff, Glenn ; Durrant, Lindy G. ; Finke, James H. ; Galon, Jerome ; Gollob, Jared A. ; Gouttefangeas, Cécile ; Grizzi, Fabio ; Guida, Michele ; Håkansson, Leif ; Hege, Kristen ; Herberman, Ronald B. ; Stephen Hodi, F. ; Hoos, Axel ; Huber, Christoph ; Hwu, Patrick ; Imai, Kohzoh ; Jaffee, Elizabeth M. ; Janetzki, Sylvia ; June, Carl H. ; Kalinski, Pawel ; Kaufman, Howard L. ; Kawakami, Koji ; Kawakami, Yutaka ; Keilholtz, Ulrich ; Khleif, Samir N. ; Kiessling, Rolf ; Kotlan, Beatrix ; Kroemer, Guido ; Lapointe, Rejean ; Levitsky, Hyam I. ; Lotze, Michael T. ; Maccalli, Cristina ; Maio, Michele ; Marschner, Jens Peter ; Mastrangelo, Michael J. ; Masucci, Giuseppe ; Melero, Ignacio ; Melief, Cornelius ; Murphy, William J. ; Nelson, Brad ; Nicolini, Andrea ; Nishimura, Michael I. ; Odunsi, Kunle ; Ohashi, Pamela S. ; O'Donnell-Tormey, Jill ; Old, Lloyd J. ; Ottensmeier, Christian ; Papamichail, Michael ; Parmiani, Giorgio ; Pawelec, Graham ; Proietti, Enrico ; Qin, Shukui ; Rees, Robert ; Ribas, Antoni ; Ridolfi, Ruggero ; Ritter, Gerd ; Rivoltini, Licia ; Romero, Pedro J. ; Salem, Mohamed L. ; Scheper, Rik J. ; Seliger, Barbara ; Sharma, Padmanee ; Shiku, Hiroshi ; Singh-Jasuja, Harpreet ; Song, Wenru ; Straten, Per Thor ; Tahara, Hideaki ; Tian, Zhigang ; van der Burg, Sjoerd H. ; von Hoegen, Paul ; Wang, Ena ; Welters, Marij J P ; Winter, Hauke ; Withington, Tara ; Wolchok, Jedd D. ; Xiao, Weihua ; Zitvogel, Laurence ; Zwierzina, Heinz ; Marincola, Francesco M. ; Gajewski, Thomas F. ; Wigginton, Jon M. ; Disis, Mary L. / Defining the critical hurdles in cancer immunotherapy. In: Journal of Translational Medicine. 2011 ; Vol. 9, No. 1.
@article{3ed4413f6ccc41258f2f46e6da5d84b2,
title = "Defining the critical hurdles in cancer immunotherapy",
abstract = "Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an {"}Immunotherapy Summit{"} with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.",
author = "Fox, {Bernard A.} and Schendel, {Dolores J.} and Butterfield, {Lisa H.} and Steinar Aamdal and Allison, {James P.} and Ascierto, {Paolo Antonio} and Atkins, {Michael B.} and Jirina Bartunkova and Lothar Bergmann and Neil Berinstein and Bonorino, {Cristina C.} and Ernest Borden and Bramson, {Jonathan L.} and Britten, {Cedrik M.} and Xuetao Cao and Carson, {William E.} and Chang, {Alfred E.} and Dainius Characiejus and {Raja Choudhury}, A. and George Coukos and {de Gruijl}, Tanja and Dillman, {Robert O.} and Harry Dolstra and Glenn Dranoff and Durrant, {Lindy G.} and Finke, {James H.} and Jerome Galon and Gollob, {Jared A.} and C{\'e}cile Gouttefangeas and Fabio Grizzi and Michele Guida and Leif H{\aa}kansson and Kristen Hege and Herberman, {Ronald B.} and {Stephen Hodi}, F. and Axel Hoos and Christoph Huber and Patrick Hwu and Kohzoh Imai and Jaffee, {Elizabeth M.} and Sylvia Janetzki and June, {Carl H.} and Pawel Kalinski and Kaufman, {Howard L.} and Koji Kawakami and Yutaka Kawakami and Ulrich Keilholtz and Khleif, {Samir N.} and Rolf Kiessling and Beatrix Kotlan and Guido Kroemer and Rejean Lapointe and Levitsky, {Hyam I.} and Lotze, {Michael T.} and Cristina Maccalli and Michele Maio and Marschner, {Jens Peter} and Mastrangelo, {Michael J.} and Giuseppe Masucci and Ignacio Melero and Cornelius Melief and Murphy, {William J.} and Brad Nelson and Andrea Nicolini and Nishimura, {Michael I.} and Kunle Odunsi and Ohashi, {Pamela S.} and Jill O'Donnell-Tormey and Old, {Lloyd J.} and Christian Ottensmeier and Michael Papamichail and Giorgio Parmiani and Graham Pawelec and Enrico Proietti and Shukui Qin and Robert Rees and Antoni Ribas and Ruggero Ridolfi and Gerd Ritter and Licia Rivoltini and Romero, {Pedro J.} and Salem, {Mohamed L.} and Scheper, {Rik J.} and Barbara Seliger and Padmanee Sharma and Hiroshi Shiku and Harpreet Singh-Jasuja and Wenru Song and Straten, {Per Thor} and Hideaki Tahara and Zhigang Tian and {van der Burg}, {Sjoerd H.} and {von Hoegen}, Paul and Ena Wang and Welters, {Marij J P} and Hauke Winter and Tara Withington and Wolchok, {Jedd D.} and Weihua Xiao and Laurence Zitvogel and Heinz Zwierzina and Marincola, {Francesco M.} and Gajewski, {Thomas F.} and Wigginton, {Jon M.} and Disis, {Mary L.}",
year = "2011",
month = "12",
day = "14",
doi = "10.1186/1479-5876-9-214",
language = "English",
volume = "9",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Defining the critical hurdles in cancer immunotherapy

AU - Fox, Bernard A.

AU - Schendel, Dolores J.

AU - Butterfield, Lisa H.

AU - Aamdal, Steinar

AU - Allison, James P.

AU - Ascierto, Paolo Antonio

AU - Atkins, Michael B.

AU - Bartunkova, Jirina

AU - Bergmann, Lothar

AU - Berinstein, Neil

AU - Bonorino, Cristina C.

AU - Borden, Ernest

AU - Bramson, Jonathan L.

AU - Britten, Cedrik M.

AU - Cao, Xuetao

AU - Carson, William E.

AU - Chang, Alfred E.

AU - Characiejus, Dainius

AU - Raja Choudhury, A.

AU - Coukos, George

AU - de Gruijl, Tanja

AU - Dillman, Robert O.

AU - Dolstra, Harry

AU - Dranoff, Glenn

AU - Durrant, Lindy G.

AU - Finke, James H.

AU - Galon, Jerome

AU - Gollob, Jared A.

AU - Gouttefangeas, Cécile

AU - Grizzi, Fabio

AU - Guida, Michele

AU - Håkansson, Leif

AU - Hege, Kristen

AU - Herberman, Ronald B.

AU - Stephen Hodi, F.

AU - Hoos, Axel

AU - Huber, Christoph

AU - Hwu, Patrick

AU - Imai, Kohzoh

AU - Jaffee, Elizabeth M.

AU - Janetzki, Sylvia

AU - June, Carl H.

AU - Kalinski, Pawel

AU - Kaufman, Howard L.

AU - Kawakami, Koji

AU - Kawakami, Yutaka

AU - Keilholtz, Ulrich

AU - Khleif, Samir N.

AU - Kiessling, Rolf

AU - Kotlan, Beatrix

AU - Kroemer, Guido

AU - Lapointe, Rejean

AU - Levitsky, Hyam I.

AU - Lotze, Michael T.

AU - Maccalli, Cristina

AU - Maio, Michele

AU - Marschner, Jens Peter

AU - Mastrangelo, Michael J.

AU - Masucci, Giuseppe

AU - Melero, Ignacio

AU - Melief, Cornelius

AU - Murphy, William J.

AU - Nelson, Brad

AU - Nicolini, Andrea

AU - Nishimura, Michael I.

AU - Odunsi, Kunle

AU - Ohashi, Pamela S.

AU - O'Donnell-Tormey, Jill

AU - Old, Lloyd J.

AU - Ottensmeier, Christian

AU - Papamichail, Michael

AU - Parmiani, Giorgio

AU - Pawelec, Graham

AU - Proietti, Enrico

AU - Qin, Shukui

AU - Rees, Robert

AU - Ribas, Antoni

AU - Ridolfi, Ruggero

AU - Ritter, Gerd

AU - Rivoltini, Licia

AU - Romero, Pedro J.

AU - Salem, Mohamed L.

AU - Scheper, Rik J.

AU - Seliger, Barbara

AU - Sharma, Padmanee

AU - Shiku, Hiroshi

AU - Singh-Jasuja, Harpreet

AU - Song, Wenru

AU - Straten, Per Thor

AU - Tahara, Hideaki

AU - Tian, Zhigang

AU - van der Burg, Sjoerd H.

AU - von Hoegen, Paul

AU - Wang, Ena

AU - Welters, Marij J P

AU - Winter, Hauke

AU - Withington, Tara

AU - Wolchok, Jedd D.

AU - Xiao, Weihua

AU - Zitvogel, Laurence

AU - Zwierzina, Heinz

AU - Marincola, Francesco M.

AU - Gajewski, Thomas F.

AU - Wigginton, Jon M.

AU - Disis, Mary L.

PY - 2011/12/14

Y1 - 2011/12/14

N2 - Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.

AB - Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=80053371253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053371253&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-9-214

DO - 10.1186/1479-5876-9-214

M3 - Article

VL - 9

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 214

ER -